← Eichor
Study identifier: NCT05596786 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial

Condition: Lung Diseases  ·  Sponsor: University Hospital, Tours

PhasePhase 3
Planned participants126
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

The main objective of the EvER-ILD2 study is to evaluate the efficacy on lung function at 6 months of one course rituximab (2 infusions) comparatively to one course of placebo (2 infusions) in a broad range of progressive ILD patients with inflammatory component.

This description comes directly from the study's public registry record.

Talk to the study team

Sylvain MARCHAND ADAM, PhD  ·  +33 2 47 47 98 34  ·  sylvain.marchand-adam@univ-tours.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Chru ToursTours, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05596786